JP5755839B2 - Ｔ細胞応答の増強方法 - Google Patents

Ｔ細胞応答の増強方法 Download PDF

Info

Publication number
JP5755839B2
JP5755839B2 JP2009549627A JP2009549627A JP5755839B2 JP 5755839 B2 JP5755839 B2 JP 5755839B2 JP 2009549627 A JP2009549627 A JP 2009549627A JP 2009549627 A JP2009549627 A JP 2009549627A JP 5755839 B2 JP5755839 B2 JP 5755839B2
Authority
JP
Japan
Prior art keywords
dose
immunogenic composition
cell
cells
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009549627A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519205A5 (enExample
JP2010519205A (ja
Inventor
クンディグ，トーマス
ボット，アドリアン
アンドリュー スミス，ケント
アンドリュー スミス，ケント
キュウ，ジヨン
Original Assignee
マンカインド コーポレイション
マンカインド コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンカインド コーポレイション, マンカインド コーポレイション filed Critical マンカインド コーポレイション
Publication of JP2010519205A publication Critical patent/JP2010519205A/ja
Publication of JP2010519205A5 publication Critical patent/JP2010519205A5/ja
Application granted granted Critical
Publication of JP5755839B2 publication Critical patent/JP5755839B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009549627A 2007-02-15 2008-02-15 Ｔ細胞応答の増強方法 Expired - Fee Related JP5755839B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90198007P 2007-02-15 2007-02-15
US60/901,980 2007-02-15
PCT/US2008/002044 WO2008100598A2 (en) 2007-02-15 2008-02-15 A method for enhancing t cell response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013242826A Division JP2014043459A (ja) 2007-02-15 2013-11-25 Ｔ細胞応答の増強方法

Publications (3)

Publication Number Publication Date
JP2010519205A JP2010519205A (ja) 2010-06-03
JP2010519205A5 JP2010519205A5 (enExample) 2011-03-31
JP5755839B2 true JP5755839B2 (ja) 2015-07-29

Family

ID=39690701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009549627A Expired - Fee Related JP5755839B2 (ja) 2007-02-15 2008-02-15 Ｔ細胞応答の増強方法
JP2013242826A Pending JP2014043459A (ja) 2007-02-15 2013-11-25 Ｔ細胞応答の増強方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013242826A Pending JP2014043459A (ja) 2007-02-15 2013-11-25 Ｔ細胞応答の増強方法

Country Status (9)

Country Link
US (1) US20080199485A1 (enExample)
EP (2) EP2481418A1 (enExample)
JP (2) JP5755839B2 (enExample)
CN (2) CN101657213B (enExample)
AU (1) AU2008216669B2 (enExample)
CA (1) CA2678353A1 (enExample)
ES (1) ES2527412T3 (enExample)
MX (1) MX2009008620A (enExample)
WO (1) WO2008100598A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
ES2413079T3 (es) 2005-06-17 2013-07-15 Mannkind Corporation Métodos y composiciones para desencadenar respuestas inmunitarias multivalentes contra epítopos dominantes y subdominantes expresados en células cancerosas y estroma tumoral
CN101702917A (zh) 2007-03-30 2010-05-05 杜克大学 一种调节核酸分子活性的方法
WO2009155332A1 (en) * 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
DE102008061522A1 (de) * 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
WO2010075525A1 (en) * 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Method of using tumor cell debris to reduce brain tumor recurrence or growth
US9468650B2 (en) 2009-09-16 2016-10-18 Duke University Inhibition of endosomal toll-like receptor activation
WO2011050344A2 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
EP2531207B1 (en) 2010-02-05 2019-10-30 Cornell University Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
US10048271B2 (en) 2012-12-11 2018-08-14 Albert Einstein College Of Medicine, Inc. Methods for high throughput receptor:ligand identification
US20150037374A1 (en) * 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
WO2015161094A1 (en) 2014-04-16 2015-10-22 Duke University Electrospun cationic nanofibers and methods of making and using the same
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017079537A1 (en) 2015-11-04 2017-05-11 Duke University Polycationic polymers for use in treating and detecting cancer
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
US11733235B2 (en) 2016-12-27 2023-08-22 Chugai Seiyaku Kabushiki Kaisha Method for evaluating immunogenicity of test substance
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
CN111135310B (zh) * 2019-12-24 2021-05-07 江苏省人民医院（南京医科大学第一附属医院） 一种定制化t细胞表位疫苗的双靶向纳米药、其制备方法及应用
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN116262779A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778879A (en) * 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE4423392A1 (de) 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
WO1996027008A2 (de) 1995-02-28 1996-09-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin Mittel zur therapie von tumoren und anderen hyperplasien
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
AU727955B2 (en) * 1996-06-12 2001-01-04 Yajun Guo Cellular vaccines and immunotherapeutics and methods for their preparation
ES2265165T3 (es) 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
ATE408690T1 (de) * 1998-03-16 2008-10-15 Alk Abello As Mutiertes rekombinantes allergen
US20030215425A1 (en) 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20020165176A1 (en) * 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
JP2005505242A (ja) * 2001-03-07 2005-02-24 マンカインド コーポレイション 癌用抗新生血管系調製物
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
NZ519363A (en) * 2002-06-05 2004-02-27 Agres Ltd A novel drug dosing regimen
US20040180354A1 (en) 2002-09-06 2004-09-16 Simard John J.L. Epitope sequences
DK1635863T3 (da) * 2003-06-17 2010-11-22 Mannkind Corp Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
EP1633387B1 (en) 2003-06-17 2012-02-22 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
US6997074B2 (en) 2003-10-30 2006-02-14 Eaton Corporation Prediction of destination gear for progressive shift feature
EP1773402A2 (en) * 2004-06-17 2007-04-18 Mannkind Corporation Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
KR20070056042A (ko) * 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
CA2592968A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP2351576A1 (en) 2004-12-29 2011-08-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
SG158155A1 (en) * 2004-12-29 2010-01-29 Mannkind Corp Methods to bypass cd+4 cells in the induction of an immune response
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens

Also Published As

Publication number Publication date
JP2014043459A (ja) 2014-03-13
HK1139595A1 (en) 2010-09-24
WO2008100598A2 (en) 2008-08-21
ES2527412T3 (es) 2015-01-23
AU2008216669A1 (en) 2008-08-21
EP2129389B1 (en) 2014-10-08
JP2010519205A (ja) 2010-06-03
AU2008216669B2 (en) 2013-12-12
CA2678353A1 (en) 2008-08-21
WO2008100598A3 (en) 2008-12-31
MX2009008620A (es) 2009-10-22
CN101657213A (zh) 2010-02-24
HK1141251A1 (en) 2010-11-05
CN103736086A (zh) 2014-04-23
EP2129389A2 (en) 2009-12-09
EP2481418A1 (en) 2012-08-01
US20080199485A1 (en) 2008-08-21
CN101657213B (zh) 2014-02-26

Similar Documents

Publication Publication Date Title
CN101657213B (zh) 用于增强t细胞应答的方法
Kayraklioglu et al. CpG oligonucleotides as vaccine adjuvants
Reed et al. Key roles of adjuvants in modern vaccines
JP2025061056A (ja) 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
JP5239041B2 (ja) 癌の治療剤
Sultan et al. Designing therapeutic cancer vaccines by mimicking viral infections
Song et al. A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity
HUP0103214A2 (hu) DNS-vakcinák
ES2900262T3 (es) Un medicamento para el uso en un método para inducir o extender una respuesta inmunitaria citotóxica celular
Akache et al. Adjuvants: engineering protective immune responses in human and veterinary vaccines
Lampe et al. High‐and low‐molecular‐weight chitosan act as adjuvants during single‐dose influenza A virus protein vaccination through distinct mechanisms
JP2009544610A (ja) 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法
MX2007008013A (es) Metodos para producir, mejorar y sostener respuestas inmunes contra epitopos i-restringidos clase mhc por propositos profilacticos o terapeuticos.
KR20130118998A (ko) 수포에 담긴 불완전 리보솜 생성물（ＤＲｉｂｂｌｅ） 및 면역 반응을 자극하기 위해 이를 이용하는 방법
JP4836957B2 (ja) ワクチンとしての、組換えマイコバクテリウムおよび生物学的に活性な作用剤の組合せ
AU2014201422B2 (en) A method for enhancing T cell response
Tahaghoghi-Hajghorbani et al. Improved immunogenicity against a Her2/neu-Derived peptide by employment of a Pan HLA DR-Binding epitope and CpG in a BALB/c mice model
HK1141251B (en) A method for enhancing t cell response
HK1174258A (en) A method for enhancing t cell response
HK1139595B (en) A method for enhancing t cell response
WO2023211279A1 (en) Adjuvant combinations for neopeptide vaccines
US20180055920A1 (en) Vaccine, therapeutic composition and methods for treating or inhibiting cancer
Chiarella et al. DNA vaccination by electrogene transfer
Huber et al. Whole-inactivated influenza virus as an adjuvant for influenza peptide antigens
Soema et al. Whole inactvated influenza virus as an adjuvant for influenza peptide antigens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130318

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140129

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150528

R150 Certificate of patent or registration of utility model

Ref document number: 5755839

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees